Moderna applies for full FDA approval of its Covid vaccine

32
12
Favorite

Moderna applies for full FDA approval of its Covid vaccine

CNBC2021-06-01

KEY POINTS Moderna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers. The mRNA vaccine is currently on the U.S. market under...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（12）

BeautyTrade
·2021-06-02
So far so good
Reply
1
Report
Jesss
·2021-06-01
RISEE!!!
Reply
Like
Report
Gabash
·2021-06-01
????
Reply
Like
Report
120PL
·2021-06-01
Moderna has full potential to cross 200
Reply
Like
Report
JazzyTizzy
·2021-06-01
Ok
Reply
1
Report
Fold Replies
- jezzytezzy:
  respond
  2021-06-02
  Reply
  Report
- jezzytezzy:
  okk
  2021-06-02
  Reply
  Report
- jezzytezzy:
  ok
  2021-06-02
  Reply
  Report
kaikk
·2021-06-01
Nice
Reply
Like
Report
Investigater
·2021-06-01
Yes
Reply
4
Report
Fold Replies
- Jennifer58:
  Yup
  2021-06-01
  Reply
  Report
JaneJane
·2021-06-01
[Miser] [Miser] [Miser]
Reply
1
Report
Meshaarias72
·2021-06-01
Wow
Reply
1
Report
Soksok
·2021-06-01
Great
Reply
2
Report
CocoPosh
·2021-06-01
Wow
Reply
3
Report
JiaJun87
·2021-06-01
[Surprised] [Surprised] [Surprised] [Surprised]
Reply
4
Report
Fold Replies
- Abundance Thankful:
  [Miser]
  2021-06-01
  Reply
  Report
- CocoPosh:
  [Miser]
  2021-06-01
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1136499588?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-01 21:15","share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","id":"1136499588","market":"us","top_or_hot":-1,"title":"Moderna applies for full FDA approval of its Covid vaccine","media":"CNBC","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Source Link</a>\n\n</div>\n","source":"cnbc_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","article_id":"1136499588","we_media_id":null,"thumbnails":[],"rights":{"source":"cnbc_highlight","url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.ArticleHeader-headline{#titleStyle#}a{#lv2TextColor#}.ArticleHeader-time, .Author-authorNameAndSocial a{#sourceStyle#;}","selectors":".PageBuilder-pageWrapper","filters":".ArticleHeader-eyebrow, .RelatedTags-relatedTags","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","pubTimestamp":1622553320,"columns":[],"sourceInfo":{"source_id":"cnbc_highlight","name":"CNBC"},"weMediaInfo":null,"summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","collect":0,"end_time":0,"defaultTopTitle":"cnbc.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"Moderna公司申请FDA批准其Covid疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":113313490,"gmtCreate":1622593866110,"gmtModify":1704186886405,"author":{"id":"3584182854667058","authorId":"3584182854667058","name":"BeautyTrade","avatar":"https://static.tigerbbs.com/63f8e238d1760fe32b24660344219105","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3584182854667058","idStr":"3584182854667058"},"htmlText":"So far so good&nbsp;","listText":"So far so good&nbsp;","text":"So far so good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/113313490","repostId":1136499588,"repostType":4,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":119475462,"gmtCreate":1622561818656,"gmtModify":1704186432561,"author":{"id":"3581132427981586","authorId":"3581132427981586","name":"Jesss","avatar":"https://static.tigerbbs.com/3d97fa229afbb5213f7f41ad230a8825","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581132427981586","idStr":"3581132427981586"},"htmlText":"RISEE!!!","listText":"RISEE!!!","text":"RISEE!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119475462","repostId":1136499588,"repostType":2,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":119460073,"gmtCreate":1622559087192,"gmtModify":1704186366026,"author":{"id":"3579576477093998","authorId":"3579576477093998","name":"Gabash","avatar":"https://static.tigerbbs.com/e5d8e2f6ed84b1a580a44d35056ee6b4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3579576477093998","idStr":"3579576477093998"},"htmlText":"????","listText":"????","text":"????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119460073","repostId":1136499588,"repostType":4,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":119550990,"gmtCreate":1622556008610,"gmtModify":1704186258600,"author":{"id":"3577829273313897","authorId":"3577829273313897","name":"120PL","avatar":"https://community-static.tradeup.com/news/c97607b34c75eab2d8d4b0216817b700","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":6,"crmLevelSwitch":1,"authorIdStr":"3577829273313897","idStr":"3577829273313897"},"htmlText":"Moderna has full potential to cross 200","listText":"Moderna has full potential to cross 200","text":"Moderna has full potential to cross 200","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119550990","repostId":1136499588,"repostType":4,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":119565484,"gmtCreate":1622555576148,"gmtModify":1704186241324,"author":{"id":"3567197540496772","authorId":"3567197540496772","name":"JazzyTizzy","avatar":"https://static.tigerbbs.com/cae924dd1adb7370389532002d192148","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3567197540496772","idStr":"3567197540496772"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/119565484","repostId":1136499588,"repostType":4,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4541768,"gmtCreate":1622609424947,"gmtModify":1680792599131,"authorId":3567197758280595,"author":{"id":3567197758280595,"idStr":"3567197758280595","authorId":3567197758280595,"name":"jezzytezzy","avatar":"https://static.tigerbbs.com/0ef706364982b2582c9190fdc988b8ee","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":119565484,"type":1,"supId":4541754,"prevId":0,"content":"<u>respond</u>","text":"<u>respond</u>","html":"<u>respond</u>"},{"id":4541756,"gmtCreate":1622609387687,"gmtModify":1680792594489,"authorId":3567197758280595,"author":{"id":3567197758280595,"idStr":"3567197758280595","authorId":3567197758280595,"name":"jezzytezzy","avatar":"https://static.tigerbbs.com/0ef706364982b2582c9190fdc988b8ee","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":119565484,"type":1,"supId":0,"prevId":0,"content":"okk","text":"okk","html":"okk"},{"id":4541754,"gmtCreate":1622609381241,"gmtModify":1680792594420,"authorId":3567197758280595,"author":{"id":3567197758280595,"idStr":"3567197758280595","authorId":3567197758280595,"name":"jezzytezzy","avatar":"https://static.tigerbbs.com/0ef706364982b2582c9190fdc988b8ee","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":119565484,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":119512498,"gmtCreate":1622554888714,"gmtModify":1704186214150,"author":{"id":"3574910578498482","authorId":"3574910578498482","name":"kaikk","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3574910578498482","idStr":"3574910578498482"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119512498","repostId":1136499588,"repostType":4,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":119510718,"gmtCreate":1622554707634,"gmtModify":1704186206382,"author":{"id":"3571011001777364","authorId":"3571011001777364","name":"Investigater","avatar":"https://static.tigerbbs.com/6cc9755a32715757af2686d3467dc2be","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3571011001777364","idStr":"3571011001777364"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/119510718","repostId":1136499588,"repostType":4,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4531769,"gmtCreate":1622554735620,"gmtModify":1680792435696,"authorId":3577529300728738,"author":{"id":3577529300728738,"idStr":"3577529300728738","authorId":3577529300728738,"name":"Jennifer58","avatar":"https://static.tigerbbs.com/9a014efda004b6cc112e5d7968adf52f","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":119510718,"type":1,"supId":0,"prevId":0,"content":"<u>Yup</u>","text":"<u>Yup</u>","html":"<u>Yup</u>"}],"langContent":"EN"},{"id":119537896,"gmtCreate":1622554626315,"gmtModify":1704186204116,"author":{"id":"3561516256982806","authorId":"3561516256982806","name":"JaneJane","avatar":"https://static.tigerbbs.com/9b18ea76092852ca384c90dd687df5f4","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":8,"crmLevelSwitch":1,"authorIdStr":"3561516256982806","idStr":"3561516256982806"},"htmlText":"[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","listText":"[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","text":"[Miser] [Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119537896","repostId":1136499588,"repostType":4,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":119595298,"gmtCreate":1622554338314,"gmtModify":1704186186900,"author":{"id":"3577781617271173","authorId":"3577781617271173","name":"Meshaarias72","avatar":"https://static.tigerbbs.com/c5282cda6a9d3948fc067b21adcb578c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3577781617271173","idStr":"3577781617271173"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119595298","repostId":1136499588,"repostType":4,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":119504928,"gmtCreate":1622553881464,"gmtModify":1704186173384,"author":{"id":"3579684763801587","authorId":"3579684763801587","name":"Soksok","avatar":"https://static.tigerbbs.com/03c4a8d2787d3c5042bccff3b0bb60f1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3579684763801587","idStr":"3579684763801587"},"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119504928","repostId":1136499588,"repostType":4,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":119501743,"gmtCreate":1622553633382,"gmtModify":1704186167354,"author":{"id":"3573299881996779","authorId":"3573299881996779","name":"CocoPosh","avatar":"https://community-static.tradeup.com/news/818138cfd3c48ea6aad706cbda48c1d6","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3573299881996779","idStr":"3573299881996779"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/119501743","repostId":1136499588,"repostType":4,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":119509777,"gmtCreate":1622553463299,"gmtModify":1704186164111,"author":{"id":"3573875235773606","authorId":"3573875235773606","name":"JiaJun87","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3573875235773606","idStr":"3573875235773606"},"htmlText":"[Surprised]&nbsp;[Surprised]&nbsp;[Surprised]&nbsp;[Surprised]&nbsp;","listText":"[Surprised]&nbsp;[Surprised]&nbsp;[Surprised]&nbsp;[Surprised]&nbsp;","text":"[Surprised] [Surprised] [Surprised] [Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/119509777","repostId":1136499588,"repostType":4,"repost":{"id":"1136499588","kind":"news","pubTimestamp":1622553320,"share":"https://ttm.financial/m/news/1136499588?lang=&edition=fundamental","pubTime":"2021-06-01 21:15","market":"us","language":"en","title":"Moderna applies for full FDA approval of its Covid vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1136499588","media":"CNBC","summary":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow ","content":"<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna applies for full FDA approval of its Covid vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna applies for full FDA approval of its Covid vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1136499588","content_text":"KEY POINTS\n\nModerna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December.\n\nModerna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.\nThe mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.\n“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”\nShares of Moderna were essentially flat in premarket trading.\nThe FDA approval process is likely to take months.\nModerna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.\nOnce companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.\nFull U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.\nModerna is the second company to seek full U.S. approval of its Covid vaccine.On May 7,Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.\nIf the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.\nModerna’s vaccine, which requires two doses given four weeks apart,has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.\nIn addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17.The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4531519,"gmtCreate":1622553498480,"gmtModify":1680792422764,"authorId":3572176137415007,"author":{"id":3572176137415007,"idStr":"3572176137415007","authorId":3572176137415007,"name":"Abundance Thankful","avatar":"https://community-static.tradeup.com/news/3596d672dc89783cd009721d4bab5ddb","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.69%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":119509777,"type":1,"supId":0,"prevId":0,"content":"[Miser]","text":"[Miser]","html":"[Miser]"},{"id":4531543,"gmtCreate":1622553658125,"gmtModify":1680792421396,"authorId":3573299881996779,"author":{"id":3573299881996779,"idStr":"3573299881996779","authorId":3573299881996779,"name":"CocoPosh","avatar":"https://community-static.tradeup.com/news/818138cfd3c48ea6aad706cbda48c1d6","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":119509777,"type":1,"supId":4531519,"prevId":0,"content":"[Miser]","text":"[Miser]","html":"[Miser]"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":32,"commentSize":12,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}